{"news_desk": "Business", "print_page": "3", "section_name": "Science", "subsection_name": null, "document_type": "article", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/08/business/08FDA/08FDA-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/08/business/08FDA/08FDA-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/01/08/business/08FDA/08FDA-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/08/business/08FDA/08FDA-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/08/business/08FDA/08FDA-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/08/business/08FDA/08FDA-thumbStandard-v2.jpg"}], "abstract": "Food and Drug Administration panel recommends approval of EP2006, more affordable version of cancer therapy drug Neupogen, also called filgrastim; if FDA acts on recommendation it will create era of competition for so-called biologic drugs, which are made out of living cells rather than synthesized from chemicals.", "type_of_material": "News", "word_count": "822", "lead_paragraph": "The group of experts endorsed a close version of the cancer drug Neupogen, which could open the door to more such biosimilar medicines.", "pub_date": "2015-01-08T00:00:00Z", "_id": "54ad726f38f0d817e02e6e0e", "byline": {"contributor": "Andrew Pollack contributed reporting from Los Angeles.", "original": "By SABRINA TAVERNISE", "person": [{"rank": 1, "role": "reported", "firstname": "Sabrina", "organization": "", "lastname": "TAVERNISE"}]}, "source": "The New York Times", "snippet": "The group of experts endorsed a close version of the cancer drug Neupogen, which could open the door to more such biosimilar medicines.", "web_url": "http://www.nytimes.com/2015/01/08/science/fda-panel-vote-biologics.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Generic Brands and Products", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "United States", "name": "glocations"}], "headline": {"main": "For First Time, F.D.A. Panel Approves Generic Copy of Costly Biologic Drug ", "print_headline": "For First Time, F.D.A. Panel Approves Generic Copy of Costly Biologic Drug"}}